Clinical utility of ustekinumab in Crohn’s disease

Paulo Gustavo Kotze¹,²
Christopher Ma¹
Abdulelah Almutairdi¹,³
Remo Panaccione¹

¹Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; ²Inflammatory Bowel Disease Outpatient Clinics, Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, Brazil; ³Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Abstract: The introduction of anti-tumor necrosis factor (TNF) therapy marked an important milestone in the management of moderate-to-severe Crohn’s disease (CD). However, there remains a pressing demand for alternative therapeutic options for patients with primary nonresponse, secondary loss of response, or intolerable side effects to conventional treatment and TNF antagonists. Ustekinumab (UST) is a fully human IgG1κ monoclonal antibody that inhibits the p40 subunit shared by the proinflammatory cytokines, the interleukin (IL)-12 and -23. This blockade leads to dampening of the inflammatory cascade and differentiation of inflammatory T cells. The clinical development program for UST in CD includes dose finding Phase II (Crohn’s Evaluation of Response to Ustekinumab Anti-Interleukin-12/23 for Induction [CERTIFI]) and the pivotal Phase III (UNITI) trials that demonstrated both the clinical efficacy and safety in anti-TNF-naive and anti-TNF-exposed patients. Real-world evidence has further defined the role of UST in CD management. In this review, we discuss the mechanism of action of UST, describe the results of the randomized controlled trials with this agent, and review the real-world efficacy and safety data from observational cohorts. Finally, we identify areas of future research in the IL-12/23 inflammatory pathway and discuss the positioning of this novel therapeutic option in CD treatment algorithms.

Keywords: ustekinumab, Crohn’s disease, interleukin

Introduction

Crohn’s disease (CD) is a progressive, pan-intestinal, systemic form of inflammatory bowel disease (IBD). Its precise etiology is not fully defined. The pathophysiology of CD is multifactorial and is influenced by genetic predisposition, environmental triggers, and increased intestinal permeability, allowing luminal antigens to enter the lamina propria to trigger an uncontrolled inflammatory cascade.¹ This results in transmural inflammation, mucosal ulceration, and complications, which include fibrostenosis, free perforation, abscess formation, and fistulae.²

The medical management of CD has traditionally been based on the use of nonspecific agents such as antibiotics and mesalamine, which have limited to no utility, corticosteroids, and immunomodulators (azathioprine [AZA], 6-mercaptopurine [6-MP], and methotrexate [MTX]). Patients with failure to conventional medical therapy are usually treated with biological agents.³ However, more recently, there has been a move toward earlier introduction of biological therapy. The first class of biological agents approved for the management of CD were tumor necrosis factor (TNF) alpha inhibitors, including infliximab (IFX), adalimumab (ADA), and certolizumab pegol.
The introduction of anti-TNF agents was revolutionary for the management of CD due to their remarkable efficacy, rapidity of onset, capacity to induce and maintain mucosal healing, and ultimately, ability to reduce or delay the need for surgery and hospitalization and alter the natural progressive course of the disease.9,10

Despite the significant response and remission rates achieved with anti-TNF agents, ~30–40% of patients are primary nonresponders and ~20–30% of patients per year experience secondary loss of response.11 Alternative targets for treatment are required for these patients with refractory disease. In the past decade, several new classes of therapy have been introduced, including anti-integrins12–14 and anti-interleukin (IL) molecules.15 Ustekinumab (UST) is a novel monoclonal antibody that inhibits IL-12 and IL-23 by blocking the common p40 subunit of these proinflammatory cytokines.16 Its efficacy has been demonstrated in landmark clinical trials for induction and maintenance of response and remission in CD patients, independent of their previous exposure to anti-TNF agents.17–19

The aim of this descriptive, nonsystematic review was to discuss the mechanism of action of UST, summarize the main findings from the UST clinical trial programs, review the real-world efficacy and safety data with UST, and examine the positioning of this novel therapeutic option in the CD management algorithm.

Why anti-IL-12/23? The mechanism of action of UST

The most widely accepted hypothesis for IBD pathogenesis is that environmental triggers in genetically predisposed individuals induce abnormalities in the innate and adaptive immune response, modulated by the presence of gut microbiota.20–22 IL-12 and IL-23 are major players in activating adaptive immunity. Targeting this proinflammatory cytokine pathway has become an area of intense therapeutic exploration in autoimmune diseases, including psoriasis, psoriatic arthritis, and CD.23

Traditionally, CD was thought to be predominantly mediated by a classical T helper cell 1 (Th1) immune response, while ulcerative colitis (UC) was thought to be primarily an atypical T helper cell 2 (Th2)-driven process.20 Recently, a new set of T helper cells producing IL-17 (Th17) have been described, challenging the Th1/Th2 paradigm. Th17 responses are implicated in the pathogenesis of CD, psoriasis, psoriatic arthritis, and other inflammatory conditions.24,25 The description of effector Th17 cells by Harrington et al26 came after the initial description of the novel cytokine IL-23 by Oppmann et al.27 This cytokine plays a major role in the expansion and stabilization of committed Th17.25,28

Interestingly, IL-23 was discovered in the process of preclinical development of UST through the discovery that it shares the same p40 subunit with IL-12.16 IL-12, formerly termed cytotoxic lymphocyte maturation factor (CLMF), was initially described by Stern et al and Guber et al.29,30 IL-12 is important for the development of Th1 cells.31 It is a heterodimeric molecule composed of two subunits (p40 and p35 chains), while IL-23 is a heterodimer that consists of covalently linked p40 and p19 protein subunits.32 The p40 protein subunit is shared between the two cytokines and is the target molecule for UST, an anti-IL-12/23p40 fully human monoclonal antibody.

Both IL-12 and -23 bind to the shared IL-12 receptor (IL-12R) β1 subunit; IL-12 binds to a heterodimeric receptor complex consisting of IL-12Rβ1 and IL-12Rβ2 chains12 expressed on the surface of T cells and natural killer (NK) cells16 and IL-23 binds to IL-12Rβ1 and IL-23 receptor (IL-23R).33 Figure 1 demonstrates the relationship between subunits and receptors of both IL-12 and IL-23 and the mechanism of inhibition of the p40 subunit by UST.

The rationale behind targeting IL-12 in inflammatory conditions was derived from two observations. First, it was identified that animal models lacking the IL-12p40 subunit were resistant to experimentally induced autoimmune disorders, including multiple gut disease models. However, this hypothesis was refined following the discovery of IL-23: animal models deficient in IL-23 but not those deficient in IL-12 were resistant to developing autoimmune diseases.24,34,35 The second observation leading to the targeting of IL-23 was derived from genome-wide association studies (GWAS), which showed a protective role of the IL-23R variant (rs11209026) in CD.36

Once dendritic cells and macrophages are activated by microbial antigens via surface toll-like receptors (TLRs), different cytokines are released including IL-12, IL-23, IL-1β, transforming growth factor-β (TGF-β), and interferon γ (IFN-γ).28,37 IL-12 plays a major role in differentiating a naive T cell to the Th1 subtype16,31 that consequently secretes TNF-α, IL-2, and IFN-γ. In contrast, IL-23 activates the secretion of IL-17A, IL-17F, and IL-22 from a previously committed Th17 cell.38 In addition, IL-23 stabilizes Th17 and prolongs its survival while suppressing T regulatory (Treg) cell subtype differentiation from a naive T cell.39,40 By inhibiting Treg differentiation, IL-23 further potentiates the inflammatory cascade.

UST is a fully human IgG1 kappa (κ) monoclonal antibody that blocks the IL-12/23 p40 subunit. This prevents the
common p40 subunit of IL-12 and IL-23 from interacting with their common receptor IL-12Rβ1 (Figure 1), leading to subsequent neutralization of human IL-12- and IL-23-mediated cell signaling, cell activation, and cytokine production, with a consequent reduction in an important step of the CD inflammatory process.

Clinical development program of UST in CD

The UST development programs comprised several important clinical trials with different designs and methodology, evaluating both clinical and objective endpoints in patient populations stratified by previous exposure to anti-TNF agents.

Phase IIa trial

The first randomized clinical trial evaluating the efficacy of UST in CD was published in 2008 by Sandborn et al. This was a double-blind cross-over study that included two different populations. Population 1 was composed of 104 patients with moderate-to-severe CD (defined by CD activity index [CDAI] between 220 and 450) and randomized in a 1:1:1:1 ratio to one of the following four groups: 1) subcutaneous (SC) placebo at weeks 0, 1, 2, and 3 and then SC 90 mg UST at weeks 8, 9, 10, and 11; 2) SC 90 mg UST at weeks 0, 1, 2, and 3 and then placebo at weeks 8, 9, 10, and 11; 3) intravenous (IV) placebo at week 0 and then 4.5 mg/kg UST at week 8; and 4) IV 4.5 mg/kg UST at week 0 and then placebo at week 8. Population 2 was an open-label study with 27 patients who were primary nonresponders or had secondary loss of response to IFX. These patients were randomized in a 1:1 ratio to receive either SC 90 mg UST at weeks 0, 1, 2, and 3 or IV 4.5 mg/kg UST at week 0. No additional treatment was administered at week 8.

The primary endpoint of the study was clinical response in population 1 at week 8, defined as a decrease in the CDAI of 25% or a CDAI of <150. Although there was a difference in clinical response rates at weeks 4 and 6 (53% UST vs 30% placebo, \( P=0.02 \)), there was no statistically significant difference between patients treated with UST and placebo at week 8 in population 1 (49 vs 40%, respectively, \( P=0.337 \)). These findings are illustrated in Figure 2. However, there was suggestion of effect modification by previous drug exposure: in population 1, patients with previous exposure to IFX (\( n=49 \)) had more significant response rates than placebo in all visits up to week 8 (\( P<0.05 \)), and in population 2, clinical response rates for patients in the combined UST group were 22 and 41% at weeks 2 and 4, respectively. At weeks 6 and 8, 48% of patients in the combined UST group demonstrated a clinical response.

Two potential explanations for the failure of this Phase IIa trial to meet the primary week 8 clinical response endpoint have been proposed: first, trial power was limited by the high placebo rate. Second, the administered UST induction dose may have been insufficient.

Phase IIb trial (Crohn’s Evaluation of Response to Ustekinumab Anti-Interleukin-12/23 for Induction [CERTIFI])

The CERTIFI study was a 36-week randomized double-blind placebo-controlled Phase IIb trial that evaluated the efficacy...
and safety of UST in CD for induction and maintenance.19 Included patients had moderate-to-severe CD (CDAI between 220 and 450) and prior nonresponse, secondary loss of response, or unacceptable adverse events to previous anti-TNF therapy.

The induction phase (weeks 0–8) included 526 patients, who were randomized into four groups (IV UST 1 mg/kg, 3 mg/kg, 6 mg/kg, and IV placebo at week 0). In the maintenance phase, patients with a response to induction with UST (defined by decrease in CDAI of 100 points) were re-randomized to receive SC 90 mg UST or placebo at weeks 8 and 16. Patients who did not have a response to placebo received placebo SC injections at weeks 8 and 16, and those who did not have a response to placebo received 270 mg of SC UST at week 8 followed by a 90 mg injection at week 16. The primary efficacy analysis was performed at week 22, and patients were followed to week 36 for the safety analysis.

The primary outcome of the CERTIFI study was clinical response (reduction in the CDAI of 100 points) at week 6, based on initial results of the aforementioned Phase IIa trial regarding optimal timing of separation from placebo.18 Secondary endpoints were clinical remission (CDAI <150) at week 6, clinical response at week 4, and clinical remission at week 22 among responders to UST at week 6.

The results of the primary endpoint of the CERTIFI study are illustrated in Figure 3. At week 6, clinical response was more prevalent in patients receiving 6 mg/kg of UST than in patients receiving placebo (39.7 vs 23.5%, Δ16.2% [95% CI, 5.1%, 27.3%], P=0.005). With respect to secondary induction outcomes, clinical remission at week 6 was observed in 10.6% of the cases in the placebo group, 16% in the UST 1 mg/kg (P=0.20) group, 15.9% in the UST 3 mg/kg (P=0.21) group, and 12.2% in the UST 6 mg/kg (P=0.68) group. Clinical response at week 4 was observed in 16.7% in the placebo group, 27.5% in the UST 1 mg/kg (P=0.04) group, 37.1% in the UST 3 mg/kg (P<0.001) group, and 30.5% in the UST 6 mg/kg (P=0.008) group.

Among responders to induction with UST, 41.7% of patients receiving 90 mg of UST in the maintenance phase were in clinical remission at week 22, as compared to 27.4% of those receiving placebo (Δ14.3% [95% CI: 2.0%, 27.1%], P=0.03).

In the induction phase, no major differences in adverse events between the four groups were observed. Infusion reactions at the first dose were similar between patients with IV UST and placebo (4.3 vs 4.5%, respectively). In the maintenance phase, the rates of adverse events, serious adverse events, and duration of follow-up were similar in the UST group as compared to placebo. There were no deaths, serious opportunistic infections, major cardiovascular events, and tuberculosis in the study. One patient from the UST 1 mg/kg group receiving 90 mg SC UST at weeks 8 and 16 developed a basal-cell carcinoma.

**Phase III trials (UNITI)**

The landmark study leading to the approval of UST for the indication of CD by regulatory agencies worldwide was the UNITI trial (A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients with Moderately-to-Severely Active Crohn’s Disease), published in 2016.17 It was composed of two identical induction studies (UNITI-1, enrolling patients with primary nonresponse, secondary
Clinical utility of UST in CD

loss of response, or unacceptable adverse events to previous anti-TNF therapy, and UNITI-2, enrolling patients who had failure or unacceptable adverse events to conventional therapy with immunomodulators or corticosteroids. The maintenance phase of the study (IM-UNITI) included patients who responded to the induction studies. All three studies were randomized, double-blind, placebo-controlled trials.

Included patients had a diagnosis of moderate-to-severe CD (CDAI 220-450) for >3 months. Inclusion was restricted to patients with positive objective inflammatory parameters (C-reactive protein [CRP] >3.0 mg/L; fecal calprotectin > 250 mg/kg; ulcerations at the ileum, colon, or both).

In the induction trials, patients were randomized at week 0 in a 1:1:1 ratio to receive 1) single dose of 130 mg of IV UST, 2) ~6 mg/kg of IV UST (patients ≤55 kg received 260 mg, those >55 and ≤85 kg received 390 mg, and those >85 kg received 520 mg), or 3) placebo. The designs of the two induction trials were identical with the only difference being the inclusion population. For the maintenance phase, patients who responded to induction were re-randomized in a 1:1:1 ratio to receive 1) 90 mg of UST SC every 8 weeks, 2) 90 mg of UST SC every 12 weeks, or 3) placebo. The designs of the two induction trials were identical with the only difference being the inclusion population. For the maintenance phase, patients who responded to induction were re-randomized in a 1:1:1 ratio to receive 1) 90 mg of UST SC every 8 weeks, 2) 90 mg of UST SC every 12 weeks, or 3) placebo for 40 weeks. They were then followed up to week 44 of the maintenance study for a total study duration of 52 weeks (8 weeks induction with 44 weeks maintenance).

The primary endpoint for the induction trials (UNITI-1 and -2) was clinical response (defined by reduction in the CDAI of 100 points) at week 6. Major secondary endpoints were clinical response and remission (CDAI <150) at week 8 and a decrease in baseline CDAI of 70 points at weeks 3 and 6. In the maintenance trial, the primary endpoint was clinical remission (CDAI <150) at week 44. Major secondary endpoints were clinical response (decrease in CDAI >100 points), maintenance of remission among those in remission at initiation of the maintenance trial, steroid-free remission, and remission exclusively in the UNITI-1 population, all assessed at week 44.

In the UNITI-1 trial, a total of 714 patients were included (247 in the placebo group, 245 in the UST 130 mg group, and 249 in the UST 6 mg/kg group). In the UNITI-2 induction study, a total of 628 patients were analyzed (210 in the placebo, 209 in the UST 130 mg group, and 209 in the UST 6 mg/kg group). There was a low percentage of discontinuation in both studies, and the baseline characteristics were similar among all study groups.

The primary endpoint results of both induction studies are described in detail in Figure 4. The response rates at week 6 were higher in all UST groups as compared with placebo in both trials. These rates were nominally higher in UNITI-2, demonstrating that previous failure to anti-TNF therapy can negatively impact the induction effect of UST. Regarding the main secondary outcome of the induction trials, clinical remission at week 8 was more prevalent in the UST groups as compared to placebo. In UNITI-1, remission rates were 7.3% for placebo, 15.9% for UST 130 mg (P=0.003), and 20.9% for UST 6 mg/kg (P<0.001). In UNITI-2, the clinical remission rates were 19.6% for placebo, 30.6% for UST 130 mg (P=0.009), and 40.2% for UST 6 mg/kg (P<0.001). As observed, remission rates were higher in the UNITI-2 population, without previous failure to anti-TNF therapy, in a similar pattern as observed for the primary outcome of clinical response at week 6.
A total of 397 patients with induction response were re-randomized for the IM-UNITI maintenance phase. Among this population, 133 patients were randomized to the placebo group, 132 patients were randomized to the UST q12 weeks group, and 132 patients were randomized to the UST q8 weeks group. Figure 5 demonstrates the remission rates at week 44 of the maintenance trial in all patients and then stratified by induction trial in separate analysis. Higher remission rates were achieved in patients receiving 90 mg SC UST q8 weeks compared to placebo in all analyses. Additionally, steroid-free remission was more prevalent in the UST-treated groups as compared to placebo (29.8% placebo vs 42.6% UST q12 weeks vs 46.9% UST q8 weeks; \( P = 0.04 \) and 0.004, respectively). Durable reductions in the CDAI, CRP, and fecal calprotectin levels were also more prevalent in the UST groups as compared to patients receiving maintenance with placebo.

In the safety analysis, adverse events were observed in \( \sim 2/3 \) of patients during the UNITI-1 trial, with no important differences between groups. Serious adverse events occurred in 4.9–7.2% of patients. In the UNITI-2 trial, adverse events were observed in \( \sim 50\% \) of patients, with serious adverse events being observed in 2.9–5.8% of the patients. At week 44 in the maintenance IM-UNITI study, at least one adverse event was observed in 81.7% of patients receiving UST 90 mg q8 weeks, 80.3% of patients receiving UST 90 mg q12 weeks, and 79.3% of patients receiving placebo.

**Figure 4** Primary endpoint results of the UNITI-1 and UNITI-2 studies.

Notes: Clinical response at week 6 was more prevalent in the UST-treated groups. In UNITI-1, \( P \)-values as compared to placebo were 0.002 (UST 130 mg) and 0.003 (UST 6 mg/kg). In UNITI-2, \( P \)-values as compared to placebo were <0.001 for both UST 130 mg and UST 6 mg/kg. Data from Feagan et al.\(^{17}\)

Abbreviation: UST, ustekinumab.

**Figure 5** Clinical remission rates at week 44 of the IM-UNITI maintenance study.

Notes: In the pooled overall UST group, \( P = 0.040 \) (q12 weeks) and \( P = 0.005 \) (q8 weeks) for UST as compared to placebo. Among patients derived from the UNITI-1 induction trial, \( P = 0.14 \) (q12 weeks) and \( P = 0.10 \) (q8 weeks). Among patients derived from UNITI-2 trial, \( P = 0.15 \) (q12 weeks) and \( P = 0.02 \) (q8 weeks). Data from Feagan et al.\(^{17}\)

Abbreviation: UST, ustekinumab.
patients in the UNITI-1, UNITI-2, and CERTIFI studies had a history of perianal fistulizing CD, a smaller proportion (10.8 and 15.5%) had active fistulas at baseline. In the CERTIFI maintenance phase, fistula response occurred in 47% (9/19) in the UST group as compared to 30% (6/20) in the placebo group at week 22. In patients from IM-UNITI study, fistula response was observed in 80% of patients in the combined UST group and 45.5% (5/11) of patients in the placebo arm (P=0.64). The authors believe that a prospective study with UST in perianal fistulas is warranted.

**Observational UST experiences**

Multiple open-label observational cohort studies have assessed the efficacy and safety of UST for CD.43–51 Primarily, these reflect retrospective treatment experiences with UST prior to regulatory approval and evaluate patients with disease refractory to conventional therapy. Open-label studies have some advantages over clinical trials. First, they reflect “real-life” data; experience with anti-TNF agents has shown that response and remission rates in clinical practice can exceed those reported in randomized controlled trials.32 Second, open-label studies allow the evaluation of therapy in populations who would otherwise be excluded from clinical trials, including patients with comorbidities and those patients who are unable or unwilling to enroll in rigorous clinical trial regimens.

However, evidence from open-label studies must be interpreted recognizing the limitations of this study design. Importantly in CD, these studies often use nonstandardized dosing regimens and nonvalidated definitions of response and remission. Second, these studies are limited by smaller sample sizes and increased loss to follow-up compared to formalized clinical trial protocols. Third, these observations are uncontrolled and there may be a tendency for both investigators and patients to overstate subjective responses to therapy. This is difficult to constrain without strict outcome definition criteria, and endpoint assessment in retrospective studies is particularly prone to recall bias.33 Nonetheless, open-label studies provide an important context in the literature for novel therapies.

**Clinical response and remission with UST**

Four multicenter cohort studies have been conducted evaluating CD patients treated with UST. Wils et al31 summarized an observational cohort of 122 consecutive CD patients refractory to anti-TNF therapy, from 20 tertiary care centers in Europe as part of the Groupe d’Etude Therapeutique des Affections Inflammatoires du Tube Digestif [Therapeutic Study Group for Inflammatory Disorders of...
the Digestive Tube] (GETAID) cohort. They demonstrated that 65% of patients had clinical benefit within 3 months of receiving UST, as defined by a significant improvement in CD-related symptoms and laboratory tests assessed by the patient’s physician with a decision to continue treatment, weaning from corticosteroids, and without surgery or rescue immunosuppression. Thirteen different UST induction regimens were used in this study, with a mean cumulative dose administered in the first month of therapy of 149 mg (±64 mg).

A second multicenter experience by Khorrami et al\(^47\) reported on 116 CD patients treated at 42 Spanish centers as part of the Spanish Ustekinumab Study group (USTEK). Clinical outcomes in this cohort were defined by the Harvey-Bradshaw Index (HBI).\(^44\) response was characterized by the reduction of ≥3 points from baseline vs remission was defined by an HBI score of ≤4. Again, multiple dosing regimens were employed, with 48% of patients receiving a cumulative induction dose >360 mg. In this cohort, 83.6% (97/116) of patients achieved a clinical benefit (response or remission) after induction therapy and 76.4% of patients had achieved a clinical benefit by 6 months of treatment.

The largest open-label UST experience, including 167 CD patients, was reported by Ma et al\(^4\) from two tertiary care centers in Alberta, Canada.\(^5\) Using more strict definitions of clinical response (decrease in HBI ≥3 points compared to baseline with complete corticosteroid tapering), 38.9 and 60.3% of patients had achieved a clinical response at 3 and 6 months, respectively. Response was stratified by induction dosing and route of drug administration (IV vs SC), with no statistically significant differences at 3 or 6 months between the 3 vs 6 mg/kg induction groups and IV vs SC induction therapy.

Finally, Harris et al\(^4\) reported efficacy outcomes of 45 patients with complicated, refractory CD treated with UST at Vanderbilt University and University of Maryland School of Medicine. All patients received a novel SC dosing regimen consisting of UST 90 mg at weeks 0, 4, and 12 with a 270 mg booster dose given at week 8 if there was no or limited clinical response. Interestingly, 87% (39/45) of patients received the 270 mg booster dose at week 8. A total of 46% of patients demonstrated a reduction in the HBI score of ≥3 points and 35% of patients achieved clinical remission.

Three single-center open-label cohorts of CD patients treated with UST have also been reported. The first experience was described in 2014 by Batista et al\(^4\) from the Mayo Clinic. Eighteen patients with CD, 89% of whom had failed at least two anti-TNF agents, were treated with SC induction UST. Cumulative probability of clinical response was 11.1% at 1 month and 44.4% at 6 months, with 26.7% able to successfully taper off corticosteroids. Subsequently, Kopylov et al\(^4\) presented a cohort of 38 CD patients from McGill University, Montreal, QC, Canada, treated with UST. A total of 95% of these patients had failed multiple biological agents, but 73.6% of them achieved an initial clinical response by the first visit after induction. Clinical response in this study was defined by improvement in patient symptoms and a decision to continue UST therapy. Follow-up results were available for 31 patients in the cohort at 6 months; 80% of initial responders had maintained response and 64.5% of patients overall were considered responding to therapy. The McGill group has subsequently reported a mixed prospective and cross-sectional cohort of UST-treated CD patients, with a primary focus on evaluating the effect of drug levels on clinical outcomes.\(^4\) Finally, in a cohort of 79 patients treated at the University of British Columbia (UBC), Vancouver, BC, Canada, Greenup et al\(^4\) demonstrated symptomatic benefit, defined by physician assessment and improvement in subjective quality of life, in 56% of patients at 3 months. A total of 47% (9/19) of patients could withdraw corticosteroids at 3 months.

**Long-term maintenance in open-label cohorts**

In open-label cohorts, 12-month clinical response rates varied from 45 to 72%. In the three multicenter cohort studies describing 12-month clinical outcomes, the reported response rate was 68% in the GETAID cohort,\(^3\) 72% in the Alberta cohort,\(^4\) and 64% in the USTEK cohort.\(^4\) Response rates based on the proportion of patients remaining on therapy in long-term follow-up are inflated by conditional censoring by drug discontinuation in nonresponders; therefore, the Alberta cohort and the USTEK cohort described the cumulative probability of maintained UST response at 12 months among all treated patients; this was similar in both cohorts (72 and 74%, respectively).\(^3,4\)

**Objective response to UST therapy in open-label cohorts**

Endoscopic, radiographic, and serologic outcomes have been assessed in several open-label studies. In the GETAID cohort, CRP response was evaluated in 58 patients with initial clinical benefit, demonstrating CRP reductions in 95% of patients, normalization in 41% of patients, and a median reduction of 18 mg/L (IQR 8–32 mg/L).\(^3\) Similarly, Kopylov et al\(^4\) reported CRP response in all clinical responders and normalization in 61.5% of patients treated with UST. Endoscopic and radiographic outcomes were most extensively assessed in the
Alberta cohort, where 141 patients had objective evaluation of disease with ileocolonoscopy, contrast-enhanced ultrasound, CT enterography, or MR enterography.\(^4\) Objective response, defined by improvement in radiographic inflammatory parameters or absence of deep mucosal ulcerations, was demonstrated in 54.5 and 55.8% of UST-treated patients at 6 and 12 months, respectively. Objective remission, defined by normalization of radiographic appearance or endoscopic mucosal healing, was achieved in 24.4 and 26.7% of UST-treated patients at 6 and 12 months, respectively. In other cohorts, endoscopic response rates range from 64 to 76%.\(^5,6\)

**Safety of UST in open-label studies**

Overall, the safety profile of UST in open-label studies has been favorable with very few reported serious adverse events. The overall adverse event rate has been demonstrated to range from 9 to 56%, although there were no placebo groups against which these rates are compared, definition for adverse events is mixed, and direct association with therapy is often unclear. For example, the most commonly reported complications include myalgias and arthralgias, infections, and headache. Whether joint-related symptoms on UST are related to withdrawal of anti-TNF therapy and subsequent flare of extraintestinal articular manifestations or whether they are directly related to UST therapy is unclear. Serious adverse events are rare, and requirement for drug discontinuation due to adverse events in open-label cohorts has been reported to be <7%.\(^4,7,8\) There does not appear to be an increased risk of malignancy, and in all cohorts, only a single death on UST treatment has been reported,\(^9\) although this was in a patient with significant pretreatment cardiopulmonary comorbidity and the cause of death was not thought to be related to therapy.

**Other issues**

In the open-label environment, dose adjustment of UST has been attempted for patients with inadequate primary response and secondary loss of response to therapy. Most frequently, patients are advanced from q8-week maintenance to q4-week maintenance therapies. Alternative strategies to consider also include reloading with high-dose SC therapy or reloading with IV induction. Reported rates of escalation are mixed, primarily due to varying indications for dose adjustment. In the McGill cohort, almost half of patients underwent dose intensification and this was successful in 11/18 (61%) patients.\(^10\) In contrast, only 3/16 (19%) patients responded to escalated maintenance dosing in the UBC cohort.\(^11\) These discrepancies may reflect differences in indication for dose escalation, use of concomitant therapy, or decision for concurrent re-induction prior to dose intensification.

Efficacy of UST for the treatment of perianal disease has been evaluated in several cohorts with promising results. In the Alberta cohort, 14/45 (31%) patients with active perianal disease at induction achieved complete radiographic healing.\(^4\) Response rates in smaller samples have also been encouraging, with 8/12 (67%) patients responding in the GETAID cohort,\(^12\) 11/18 (61%) patients responding in the USTEK cohort,\(^13\) and 9/13 (69%) patients responding in the McGill cohort.\(^14\) Open-label evidence for the efficacy of UST for other extraintestinal manifestations of CD remains sparse.

Potential predictors of UST response in univariate and multivariate models derived from observational cohorts have been inconsistent, and regression model power has been generally limited by small sample size. Concurrent immunomodulation was identified as a positive predictor of induction response in the GETAID cohort and of maintenance response in both the Alberta and USTEK cohorts.\(^15\) This was not replicated in subgroup analysis of the UNITI program, and the potential biological mechanisms are unclear, as the immunogenicity to UST is low\(^16\) and serum UST levels have not been shown to significantly vary with immunomodulator use.\(^17\) Battat et al evaluated serum trough UST concentrations associated with clinical and endoscopic responses: they demonstrated that 26-week threshold UST level of 4.5 µg/mL was associated with endoscopic response.\(^18\) Other potential negative predictors of response include previous surgical resection\(^19\) and prior primary anti-TNF nonresponse.\(^20\) A summary of significant relevance and weaknesses of the included open-label studies with UST is presented in Table 1.

**Future directions**

**Use of UST today and tomorrow**

With the mounting evidence for both safety and efficacy from randomized controlled trials and open-label real-world cohorts, we anticipate that UST will become an increasingly important part of the therapeutic armamentarium for the management of moderate-to-severe CD. In particular, as the number of patients with loss of response to anti-TNF therapy increases over time, second-line biological therapies such as UST will be needed to manage this difficult-to-treat population with refractory disease. However, there are still many unanswered questions regarding the optimal use of UST that need to be addressed.

First, the positioning of UST in the therapeutic algorithm for CD is not defined.\(^21\) It has been extensively studied after...
the failure of conventional therapy and anti-TNF agents, and whether using UST as a first-line biologic achieves better long-term outcomes in moderate-to-severe CD is unclear. Previous anti-TNF failure is associated with nominally lower response rates in the UNITI trial program and has been associated with poorer response in open-label studies. However, there are currently no head-to-head comparisons of UST vs either anti-TNF or anti-integrin as first-line therapy. This specific question is currently being evaluated in a prospective open-label cohort study (Clinicaltrials.gov: NCT03108326).

Furthermore, the positioning of UST as a second-line agent after anti-TNF failure is debatable. There are no data to support the use of UST over anti-integrin molecules such as vedolizumab or over oral small molecule therapy. Factors such as patient preference for ease of SC administration and presence of extraintestinal manifestations may play a role in deciding on second-line treatment options. However, the clinical “gestalt” that UST is superior to vedolizumab with respect to overall efficacy, rapidity of onset, efficacy in small bowel disease, and achievement of endoscopic or histologic healing is largely unfounded. As more agents are introduced as treatment options in CD, the positioning of UST in the treatment algorithm may change.

Third, there remain unanswered questions regarding the optimal conditions for UST administration. Future research should consider whether 1) UST induction should be bridged with corticosteroids or other therapy, 2) concomitant immunomodulator therapy is beneficial or specific subgroups of patients benefit from concomitant immunomodulators, 3) combination therapy with other classes of biological agents is safe and effective for severe disease, and 4) prospective therapeutic drug monitoring improves long-term outcomes in UST-treated patients. Finally, as with all novel therapies, postmarketing studies are needed to carefully monitor for safety signals of rare adverse events not captured in finite clinical trial programs.

**Beyond UST: selective IL-23 blockade**

Although the efficacy of blocking both IL-12 and IL-23 has been well demonstrated, an exciting horizon in the targeting of this inflammatory pathway is selective IL-23 blockade. The rationale for IL-23 selective blockade is twofold: first, IL-23 appears to be the critical step in disease pathogenesis in murine models. Second, targeting the unique p19 subunit of IL-23 would allow normal IL-12-mediated Th1 responses that mediate host protection against mycobacterial disease.

### Table 1 Summary of open-label cohorts of UST for Crohn’s disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Relevance</th>
<th>Weakness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batista et al (2014)</td>
<td>First reported OLC experience with UST</td>
<td>Limited sample size (n=18)</td>
</tr>
<tr>
<td>Reported mucosal healing experience</td>
<td>Abstract only</td>
<td></td>
</tr>
<tr>
<td>Kopylov et al (2014)</td>
<td>Uniform population of anti-TNF failure patients</td>
<td>Absence of validated clinical scores for disease activity</td>
</tr>
<tr>
<td>First OLC to evaluate efficacy of dose escalation of UST</td>
<td>Heterogeneity in dosing regimens</td>
<td></td>
</tr>
<tr>
<td>Composite endpoint including surgery, corticosteroid weaning, and avoidance of rescue immunosuppressants</td>
<td>Heterogeneity in dosing regimens</td>
<td></td>
</tr>
<tr>
<td>Khorrami et al (2016)</td>
<td>Multicenter cohort (Spanish USTEK)</td>
<td>Minimal evaluation of objective endpoints (endoscopy, fecal calprotectin)</td>
</tr>
<tr>
<td>Evaluated predictors of long-term UST failure</td>
<td>Heterogeneity in dosing regimens</td>
<td></td>
</tr>
<tr>
<td>Harris et al (2016)</td>
<td>Fixed dosing regimen, administered SC but designed to mimic IV dosing</td>
<td>Limited sample size (n=45)</td>
</tr>
<tr>
<td>Outcome evaluation using both HBI and short IBD questionnaire</td>
<td>Missing data from retrospective collection</td>
<td></td>
</tr>
<tr>
<td>Ma et al (2017) (two studies)</td>
<td>Evaluated both short- and long-term outcomes, both endoscopic, radiographic, and clinical outcomes</td>
<td>Heterogeneity in dosing regimens</td>
</tr>
<tr>
<td>Largest sample size (n=167)</td>
<td>Nonvalidated definitions of endoscopic and radiographic endpoints</td>
<td></td>
</tr>
<tr>
<td>Evaluated clinical, biomarker, and endoscopic endpoints</td>
<td>Off-label SC induction dosing regimen</td>
<td></td>
</tr>
<tr>
<td>Evaluated combination of short-term and long-term, symptomatic and objective responses</td>
<td>Off-label SC induction dosing regimen</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** GETAID, [Therapeutic Study Group for Inflammatory Disorders of the Digestive Tube]; HBI, Harvey-Bradshaw Index; IBD, inflammatory bowel disease; IV, intravenous; SC, subcutaneous; TNF, tumor necrosis factor; UST, ustekinumab; USTEK, Spanish Ustekinumab Study group; OLC, open label cohort; IQR, interquartile range; CT, computed tomography; MR, magnetic resonance.
Thus, the aim of IL-23-specific blockers would be to reduce inflammatory disease burden while preserving host immunity and reducing off-target adverse events.57

Several IL-23-specific monoclonal antibodies are in clinical trial development programs, including brazikumab, risankizumab, tildrakizumab, and guselkumab.57 Phase II trials of risankizumab and brazikumab in CD patients have been completed with promising results.58,59 In a randomized controlled trial of 121 CD patients (93% with previous anti-TNF exposure), Feagan et al58 reported that 31% of risankizumab-treated patients achieved week 12 clinical remission compared to 15% of placebo-treated patients (P=0.0489). Similarly, in the Phase IIa trial of 121 patients with moderate-to-severe CD failing or intolerant to anti-TNF therapy, 49.2% of brazikumab-treated patients achieved clinical response or remission compared to 26.7% of patients receiving placebo (P=0.010).59

Finally, perhaps the most intriguing evidence for IL-23 selective inhibition has recently been published in the psoriasis literature. In a head-to-head Phase II randomized trial of risankizumab vs UST in 166 patients with psoriasis, achievement of the primary endpoint of 90% reduction in baseline Psoriasis Area and Severity Index (PASI) score at week 12 occurred in 77% (64/83) of risankizumab-treated patients compared to only 40% (16/40) of UST-treated patients (P<0.001).60 Although translation of these results to the CD population is limited by differences in disease pathogenesis and burden of systemic inflammation, the story of IL-23 selective inhibitors in CD will certainly continue to evolve over the next decade.

Conclusion
The inhibition of the IL-12 and -23 pathways has been demonstrated to be an effective strategy in the management of CD. In pivotal randomized controlled trials and multiple real-world observational cohorts, UST is safe and effective for the induction and maintenance of response and remission, in both anti-TNF-naive and anti-TNF-exposed CD patients. However, the optimal treatment strategy and positioning of UST in the CD management algorithm remain undefined and these decisions should be individualized and discussed with patients. Future studies are needed to delineate the efficacy of UST for UC, determine the effect of concomitant immunomodulator use, and optimize implementation of therapeutic drug monitoring with UST. These pathways will continue to be paved with increased experience and expertise with UST over time.

Disclosure
CM is supported in part by the Canadian Institutes of Health Research and the Canadian Association of Gastroenterology. PKG has received consulting fees from AbbVie, Takeda, and Pfizer and speaker’s bureau fees from AbbVie, Takeda, Ferring, Pfizer, UCB, and Janssen. RP has received scientific advisory board fees from Abbott/AbbVie, Amgen, Janssen, Merck, Pfizer, Prometheus Laboratories, Salix Pharma, Shire, Takeda, and Warner Chilcott, consulting fees from AbbV/ AbbVie, Amgen, Aptalis, Astra Zeneca, Baxter, BMS, Centocor, Elan/Biogen, Eisai, Ferring, GSK, Janssen, Merck, Millennium, Pfizer, Proctor & Gamble, Prometheus Therapeutics and Diagnostics, Schering-Plough, Shire, Takeda, UCB Pharma, and Warner Chilcott, research grants from Abbott/AbbVie, Amgen, Aptalis, Astra Zeneca, Baxter, BMS, Centocor, Eisai, Elan/Biogen, Ferring, GSK, Janssen, Merck, Millennium, Pfizer, Proctor & Gamble, Prometheus, Shire, Schering-Plough, Takeda, UCB Pharma, and Warner Chilcott, and speaker’s bureau fees from Abbott/AbbVie, Amgen, Aptalis, Astra Zeneca, Baxter, BMS, Centocor, Eisai, Elan/Biogen, Ferring, GSK, Janssen, Merck, Millennium, Pfizer, Proctor & Gamble, Prometheus, Schering-Plough, Shire, Takeda, UCB Pharma, and Warner Chilcott. The authors report no other conflicts of interest in this work.

References


